Abbott Laboratories (NYSE:ABT – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twenty-eight ratings firms that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $119.80.
ABT has been the subject of a number of research analyst reports. BTIG Research lifted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. TD Cowen reiterated a “buy” rating and set a $135.00 target price on shares of Abbott Laboratories in a research note on Tuesday, September 8th. Wells Fargo & Company increased their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, Citigroup raised their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th.
Read Our Latest Stock Analysis on Abbott Laboratories
Hedge Funds Weigh In On Abbott Laboratories
Abbott Laboratories Price Performance
Shares of NYSE ABT opened at $97.52 on Thursday. The firm has a market cap of $168.75 billion, a P/E ratio of 31.56, a PEG ratio of 1.81 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $135.37. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average of $106.99 and a 200 day moving average of $98.68.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. The company’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.
More Abbott Laboratories News
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Rothschild & Co Redburn upgraded Abbott from “neutral” to “buy” and raised its price target to $127 from $119. The new target implies roughly 30% upside from the referenced trading level, providing the clearest catalyst for the stock’s recent strength. Rothschild & Co Redburn upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT
- Positive Sentiment: Abbott is included among low-beta healthcare stocks viewed as relatively defensive amid interest-rate uncertainty and market volatility. Its diversified healthcare portfolio and dividend profile may appeal to investors seeking stability. Low-Beta Healthcare Stocks to Buy
- Positive Sentiment: Industry forecasts point to continued growth in disposable medical sensors and biomarkers, markets that include Abbott and could support longer-term demand for its diagnostics and monitoring products. Disposable Medical Sensors Market Forecasts Growth
- Neutral Sentiment: Analysts expect Abbott’s upcoming third-quarter report to show single-digit earnings growth. The results and management outlook will be important for validating the bullish price-target revision. Abbott Laboratories Quarterly Earnings Preview
- Negative Sentiment: Abbott recently underperformed the broader market, and its price remains below the 50-day moving average, indicating lingering technical pressure despite the analyst upgrade. Abbott Sees a More Significant Dip Than the Broader Market
About Abbott Laboratories
Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.
Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.
Read More
- Five stocks we like better than Abbott Laboratories
- Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
